173 related articles for article (PubMed ID: 34710285)
21. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
22. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
23. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory myofibroblastic tumors of the central nervous system that express anaplastic lymphoma kinase have a high recurrence rate.
Denis DJ; Elayoubi K; Weil AG; Berthelet F; Bojanowski MW
Surg Neurol Int; 2013; 4():70. PubMed ID: 23776756
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
26. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
[TBL] [Abstract][Full Text] [Related]
27. ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.
Xu X; Li H; Peng K; Yu Y; Chen L; Fang Y; Sun Y; Hou Y; Liu T
Oncol Lett; 2019 Feb; 17(2):2370-2376. PubMed ID: 30675302
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors.
Trahair T; Gifford AJ; Fordham A; Mayoh C; Fadia M; Lukeis R; Wood AC; Valvi S; Walker RD; Blackburn J; Heyer EE; Mercer TR; Barbaric D; Marshall GM; MacKenzie KL
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914017
[TBL] [Abstract][Full Text] [Related]
29. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study.
Cook JR; Dehner LP; Collins MH; Ma Z; Morris SW; Coffin CM; Hill DA
Am J Surg Pathol; 2001 Nov; 25(11):1364-71. PubMed ID: 11684952
[TBL] [Abstract][Full Text] [Related]
30. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.
Kaino A; Niizuma H; Katayama S; Irie M; Nakano T; Sato D; Saito T; Kato S; Suehara Y; Sasahara Y; Kikuchi A
Pediatr Blood Cancer; 2023 Aug; 70(8):e30330. PubMed ID: 37017194
[No Abstract] [Full Text] [Related]
31. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study.
Liu X; Gong C; Zhang J; Feng W; Guo Y; Sang Y; Wang C; Chen Y; Wang J; Yu L; Zhang X; Luo Z
Cancer Res Treat; 2023 Jul; 55(3):1001-1010. PubMed ID: 36915248
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic Lymphoma Kinase Positive Mesenteric Inflammatory Myofibroblastic Tumor in Adult Woman.
Lee CS; Kim JS; Rodriguez R; Krell RW
Cureus; 2022 Apr; 14(4):e24422. PubMed ID: 35637807
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
Wang K; Guo R; Siegal GP; Wei S
Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
36. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS.
Vidrine DW; Berry JF; Garbuzov A; Falcon C; Tubbs RS; Bui CJ
Childs Nerv Syst; 2021 Jul; 37(7):2147-2151. PubMed ID: 34014367
[TBL] [Abstract][Full Text] [Related]
37. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
[TBL] [Abstract][Full Text] [Related]
39. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.
Durham C; Clemons M; Alias A; Konduri K
Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049
[TBL] [Abstract][Full Text] [Related]
40. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
